{
    "nctId": "NCT03303846",
    "briefTitle": "Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients",
    "officialTitle": "Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Healthy Subject",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "SCREENING",
    "enrollmentCount": 344,
    "primaryOutcomeMeasure": "Incidence of triple-negative breast cancer (invasive and/or ductal carcinoma in situ [DCIS]) within the 12-month period of the study",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women who are undergoing screening breast MRI as per standard of care for high-risk breast cancer screening\n* Willing to donate left-over tissue if patient undergoes a breast biopsy and/or breast surgery\n* Willing to have about 40 mL of blood (approximately 3 tablespoons) drawn\n* Documented informed consent of the participant\n\nExclusion Criteria:\n\n* Allergy or intolerance to gadolinium\n* Inability to undergo breast MRI (e.g. claustrophobia)\n* Participants with active cancer diagnosis (exception: skin cancer, biopsy-proven atypical lobular, ductal hyperplasia and/or lobular carcinoma in situ)\n* Previous diagnosis of stage 4 cancer\n* Participants who have received cytotoxic chemotherapy within 1 year prior to screening breast MRI\n* Participants who have received endocrine therapy within 1 year prior to screening breast MRI\n* Participants who have received breast radiation within 1 year prior to screening breast MRI\n* Radiation to both breasts\n* Pregnant and/or lactating within 1 year prior to screening breast MRI\n* Receives screening breast MRIs at an outside facility other than the consenting institution",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}